NT2020
NT2020
T Cell Activator (PROTAC)
NT2020 utilizes the protein-targeting function of the PROTAC platform to remove specific target proteins. By targeting and eliminating certain proteins specifically expressed by T cells, T cell activity is enhanced. As a result, NT2020 serves as a T cell activator, further enhancing the anti-tumor effect of T cells.
In 2020, Ubix Therapeutics introduced CRBN (Cereblon), which can target the E3 ligase. We are building upon this structure to develop a final compound that incorporates targeting of the E3 ligase into the PROTAC system.
Target Indication: undisclosed
In 2020, Ubix Therapeutics introduced CRBN (Cereblon), which can target the E3 ligase. We are building upon this structure to develop a final compound that incorporates targeting of the E3 ligase into the PROTAC system.
Target Indication: undisclosed
NT2020 Mode of Action
